Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results from the phase IB KEYNOTE-028 trial

Journal of Clinical Oncology

Volumn 35, Issue 36, 2017, Pages 4035-4041

  Frenel, Jean Sebastien ^a   Le Tourneau, Christophe ^b   O'Neil, Bert ^e   Ott, Patrick A ^f   Piha Paul, Sarina A ^g   Gomez Roca, Carlos ^c   Van Brummelen, Emilie M J ^h   Rugo, Hope S ⁱ   Thomas, Shari ^j   Saraf, Sanatan ^j   Rangwala, Reshma ^j   Varga, Andrea ^d  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e INDIANA UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLITIS; CONFERENCE PAPER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FEVER; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MULTICENTER STUDY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; XEROSTOMIA; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; UTERINE CERVIX TUMOR;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 85038389723     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.5471     Document Type: Conference Paper

References (38)

1. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
2. International Agency for Research on Cancer: Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan. iarc.fr/Pages/fact-sheets-population. aspx
3. American Cancer Society: Cancer facts and figures 2016. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annualcancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf
4. National Cancer Institute: Cancer stat facts: Cervix uteri cancer. https://seer.cancer.gov/statfacts/html/cervix.htm
5. Pfaendler KS, Tewari KS: Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214:22-30, 2016
6. National Comprehensive Cancer Network: National Comprehensive Cancer Network clinical practice guidelines. Oncology: Cervical cancer-Version 1.2017. https://www.nccn.org/professionals/physician-gls/pdf/cervical.pdf
7. Colombo N, Carinelli S, Colombo A, et al: Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23: vii27-vii32, 2012 (suppl 7)
8. Long HJ III, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 23:4626-4633, 2005
9. Monk BJ, Sill MW, McMeekin DS, et al: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 27:4649-4655, 2009
10. Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma ofthe cervix: A gynecologic oncology group study. J Clin Oncol 22:3113-3119, 2004
11. Tewari KS, Sill MW, Long HJ III, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-743, 2014
12. Okazaki T, Chikuma S, Iwai Y, et al: A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212-1218, 2013
13. Iwai Y, Ishida M, Tanaka Y, et al: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297, 2002
14. Dong H, Strome SE, Salomao DR, et al: Tumorassociated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8:793-800, 2002
15. Keytruda (pembrolizumab) for injection, for intravenous use [package insert]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp, 2017
16. Khoja L, Butler MO, Kang SP, et al: Pembrolizumab. J Immunother Cancer 3:36, 2015
17. Keytruda [summary of product characteristics]. Merck Sharp and Dohme Limited, Hoddesdon, UK, 2017
18. Heeren AM, Punt S, Bleeker MC, et al: Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 29:753-763, 2016
19. Mezache L, Paniccia B, Nyinawabera A, et al: Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 28:1594-1602, 2015
20. Dolled-Filhart M, Roach C, Toland G, et al: Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 140:1243-1249, 2016
21. Muro K, Chung HC, Shankaran V, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol 17:717-726, 2016
22. Zhu H, Luo H, Zhang W, et al: Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther 10:1885-1895, 2016
23. Mannel RS, Blessing JA, Boike G: Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: A phase II trial of the Gynecologic Oncology Group. Gynecol Oncol 79:64-66, 2000
24. Muderspach LI, Blessing JA, Levenback C, et al: A phase II study of topotecan in patients with squamous cell carcinoma of the cervix: A gynecologic oncology group study. Gynecol Oncol 81:213-215, 2001
25. Fracasso PM, Blessing JA, Wolf J, et al: Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A gynecologic oncology group study. Gynecol Oncol 90:177-180, 2003
26. Muggia FM, Blessing JA, Method M, et al: Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 92:639-643, 2004
27. Schilder RJ, Blessing JA, Morgan M, et al: Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group. Gynecol Oncol 76:204-207, 2000
28. Garcia AA, Blessing JA, Vaccarello L, et al: Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Am J Clin Oncol 30:428-431, 2007
29. Look KY, Blessing JA, Michener CM, et al: Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Int J Gynecol Cancer 18:773-778, 2008
30. Schilder RJ, Sill MW, Lee YC, et al: A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Int J Gynecol Cancer 19:929-933, 2009
31. Monk BJ, Sill MW, Burger RA, et al: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 27:1069-1074, 2009
32. Santin AD, Sill MW, McMeekin DS, et al: Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 122:495-500, 2011
33. Look KY, Blessing JA, Gallup DG, et al: A phase II trial of 5-fluorouracil and high-dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Am J Clin Oncol 19:439-441, 1996
34. Opdivo (nivolumab) injection, for intravenous use [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2017
35. Tecentriq (atezolizumab) injection, for intravenous use [package insert]. South San Francisco, CA: Genentech, Inc, 2017
36. Lyford-Pike S, Peng S, Young GD, et al: Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73:1733-1741, 2013
37. Partlová S, Bouček J, Kloudová K, et al: Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. OncoImmunology 4:e965570, 2015
38. Hollebecque A, Meyer T, Nadine Moore K: et al: An open-label, multicohort, phase 1/2 study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic cervical, vaginal, and vulvar cancers. Presented at American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2-6, 2017 (abstr 5504)